Nazif-Munoz José Ignacio, Martínez Pablo, Huỳnh Christophe, Massamba Victoria, Zefania Isaora, Rochette Louis, Vasiliadis Helen-Maria
Faculté de médecine et des sciences de la santé, Université de Sherbrooke-Campus Longueuil, Longueuil, Quebec, Canada.
Centre de recherche Charles-Le Moyne, Longueuil, Quebec, Canada.
Addiction. 2024 Oct;119(10):1784-1791. doi: 10.1111/add.16564. Epub 2024 Jun 19.
Public health concerns regarding pregnant women's health after the enactment of the Cannabis Act in Canada (CAC) (a law that allowed non-medical cannabis use), and the potential impact of the COVID-19 pandemic, call for a contemporary assessment of these two events. Our study measured associations between the CAC, the COVID-19 pandemic and the monthly prevalence rates of cannabis-, all drug- and alcohol-related diagnosed disorders among pregnant women in the province of Quebec.
DESIGN, SETTING AND PARTICIPANTS: This was a quasi-experimental design applying an interrupted time-series methodology in the province of Quebec, Canada. The participants were pregnant women aged 15-49 years, between January 2010 and July 2022.
Administrative health data from the Québec Integrated Chronic Disease Surveillance System were used to classify pregnant women according to cannabis-, all drug (excluding cannabis)- and alcohol-related disorders. The CAC (October 2018) and the COVID-19 pandemic (April 2020) were evaluated as (1) slope changes and (2) level changes. Cannabis-, all drug (excluding cannabis)- and alcohol-related disorders were measured by total monthly age-standardized monthly prevalence rate of each disorder for pregnant women aged 15-49 years.
Before the CAC, the prevalence rate of cannabis-related diagnosed disorders significantly increased each month by 0.5% [95% confidence interval (CI) = 0.3-0.6] in the pregnant population. After the CAC, there were significant increases of 24% (95% CI = 1-53) of cannabis-related diagnosed disorders. No significant changes were observed for all drug (excluding cannabis)- and alcohol-related diagnosed disorders associated with the CAC. A non-significant decrease of 20% (95% CI = -38 to 3) was observed during the COVID-19 pandemic in alcohol-related disorders.
The monthly incidence rates of diagnosed cannabis-related disorders in pregnant women in Quebec increased significantly following the enactment of the Cannabis Act in Canada. Diagnoses of all drug (excluding cannabis)- and alcohol-related disorders remained relatively stable.
在加拿大《大麻法案》（一项允许非医疗用途大麻使用的法律）颁布后，公众对孕妇健康的担忧，以及新冠疫情的潜在影响，都需要对这两个事件进行当代评估。我们的研究测量了《大麻法案》、新冠疫情与魁北克省孕妇中与大麻、所有药物和酒精相关的诊断疾病的月度患病率之间的关联。
设计、背景与参与者：这是一项在加拿大魁北克省采用中断时间序列方法的准实验设计。参与者为2010年1月至2022年7月期间年龄在15 - 49岁的孕妇。
来自魁北克综合慢性病监测系统的行政健康数据用于根据与大麻、所有药物（不包括大麻）和酒精相关的疾病对孕妇进行分类。评估《大麻法案》（2018年10月）和新冠疫情（2020年4月）的影响为：（1）斜率变化和（2）水平变化。与大麻、所有药物（不包括大麻）和酒精相关的疾病通过15 - 49岁孕妇每种疾病的每月年龄标准化总患病率来衡量。
在《大麻法案》颁布前，孕妇群体中与大麻相关的诊断疾病患病率每月显著增加0.5%[95%置信区间（CI）= 0.3 - 0.6]。《大麻法案》颁布后，与大麻相关的诊断疾病显著增加了24%（95% CI = 1 - 53）。与《大麻法案》相关的所有药物（不包括大麻）和酒精相关的诊断疾病未观察到显著变化。在新冠疫情期间，与酒精相关的疾病患病率出现了20%的非显著下降（95% CI = -38至3）。
加拿大《大麻法案》颁布后，魁北克省孕妇中与大麻相关的诊断疾病的月度发病率显著增加。所有药物（不包括大麻）和酒精相关疾病的诊断保持相对稳定。
